Population-based study on the association between autoimmune disease and lymphoma: National Health Insurance Service-National Sample Cohort 2002–2015 in Korea

Sarcoidosis and lymphoma mortality risk: An observational study from the Spanish National Registry

“…Similarly, a very recent study from Ungprasert et al neither showed a higher risk of haematological or lymphoproliferative malignancy in patients with sarcoidosis compared to non-sarcoidosis subjects [ 23 ]. Finally, a population-based study from Korea published in 2021, despite confirming a higher risk from lymphoma in patients with sarcoidosis, showed that lymphoma diagnosis practically coincided with sarcoidosis onset and diagnosis, unlike lymphoma in patients with rheumatoid arthritis or Sjögren's syndrome [ 20 ]. The above differences probably reflect the complex relationship between the two entities and the ‘sarcoidosis-lymphoma syndrome’ concept ambiguity.…”

“…Cases with limited cutaneous sarcoidosis (D86.3), without affecting any other organ or presenting systemic features, were not included. Furthermore, patients who presented any other autoimmune disease which might impact the neoplasm related risk in the sarcoidosis population were also excluded [ [19] , [20] , [21] , [22] ]. These conditions were also identified according to the respective ICD-10-CM diagnostic codes, including systemic lupus erythematosus (SLE) (M32), Sjögren's syndrome (SjS) (M35), systemic sclerosis (SSc) (M34), dermato-polymyositis (DM/PM) (M33), rheumatoid arthritis (RA) (M05 and M06), ankylosing spondylitis (AS) (M45), psoriasis (L40), myasthenia gravis (MG) (G70.0) or inflammatory bowel disease (IBD) (K50 and K51).…”